Paris-based Exeliom Biosciences, a clinical-stage BioTech firm growing new therapies in immuno-oncology and immuno-inflammation, at this time introduced the completion of a €2.85 million extension to its Collection A spherical, bringing the entire Collection A funding to €11.85 million.
This extension, led by present buyers Biocodex with participation by Crescent Ventures, UI Investissement and Forepont Capital Companions, builds on the corporate’s legacy of practically €30 million in dilutive and non-dilutive funding since its founding in 2016.
“Exeliom is deeply grateful for the unwavering assist of our buyers, which has enabled us to rework EXL01 from a microbiome remedy right into a precision NOD2-targeting immunomodulator, utilizing a dwell bacterial pressure as its supply mode,” stated Benjamin Hadida, CEO of Exeliom.
This funding matches inside a wider sample of funding in European immuno-oncology and immuno-inflammation ventures throughout 2025.
In Finland, TILT Biotherapeutics raised €22.6 million in a Collection B spherical to progress intravenously delivered most cancers immunotherapies. Within the UK and Eire, LIfT BioSciences secured €12 million to advance neutrophil-based immunotherapies for strong tumours. Denmark’s SNIPR Biome obtained €35 million in Collection B funding for microbial and CRISPR-based therapeutics addressing oncology and infectious illnesses.
In the meantime, Spain’s Spotlight Therapeutics raised €15 million to speed up medical growth of its skin-tumour immunotherapies, and Austria’s Graph Therapeutics accomplished a €3 million pre-Seed spherical for AI-driven discovery in irritation and immunology.
Exeliom’s Collection A extension due to this fact displays continued investor confidence in precision-based immunotherapies, positioning France alongside a various set of European friends advancing immune-modulating platforms.
EU-Startups beforehand lined Exeliom Biosciences in July 2023, after we reported on the corporate’s €24 million Collection A near advance its microbiome-based immunotherapy pipeline.
“The evolution of this small-molecule-like strategy unlocks new indications, not solely increasing our therapeutic potential but in addition positioning us for worldwide development, together with a brand new most cancers examine underway within the US,” added Hadida.
Based in 2016, Exeliom Biosciences is a clinical-stage BioTech firm growing a brand new era of innate immune modulators to revive and improve sufferers’ immune responsiveness in most cancers, inflammatory illnesses and power infections.
The brand new funding will assist the continued medical growth and worldwide growth of Exeliom’s lead programme, EXL01, with a deal with advancing proof-of-concept Part 2 research and making ready for a brand new most cancers indication within the US.
Their lead candidate, EXL01, is a bacterial-derived, NOD2-targeting immunomodulator that prompts macrophages and reprograms the immune microenvironment. By doing so, EXL01 has the potential to beat resistance to present therapies and considerably improve the efficacy of immunotherapies.
EXL01 is presently being evaluated in three Part 2 oncology trials together with immune checkpoint inhibitors, together with the biggest randomized Part 2 examine worldwide evaluating a bacterial strategy in gastric most cancers. As well as, EXL01 has accomplished a Part 1 examine in Crohn’s illness and is now being investigated in a randomised, placebo-controlled Part 2 trial in the identical illness.
The programme additionally features a Part 2 randomised, placebo-controlled trial for the prevention of recurrent Clostridioides difficile an infection.
“Supporting Exeliom Biosciences completely embodies a partnership rooted in scientific excellence, guided by long-term imaginative and prescient and pushed by our shared conviction that microbiota-based innovation can remodel the administration of complicated immune-mediated illnesses. Collectively, we purpose to show pioneering science into sustainable well being options for sufferers worldwide,” stated Jean-Marie Lefevre, chairman of Biocodex.
Over the previous two years, Exeliom has made important strides in demonstrating the mechanism of motion of EXL01, figuring out NOD2 as its key goal.
The NOD2 pathway is a central element of the physique’s innate immune system and a well-validated goal within the pharmaceutical trade, with two permitted merchandise already available on the market. EXL01 displays superior NOD2-agonist properties and prompts a definite NOD2 signaling profile in comparison with present approaches, positioning it as a probably first-in-class remedy on this rising area.
“Forepont Capital are excited on the scientific and medical developments made by Exeliom, significantly that Faecalibacterium prausnitzii modulates the immune system by way of the NOD2 pathway, which is vital for regulating innate immunity and is due to this fact an vital goal for therapeutics,” stated Ismail Kola, senior associate at Forepont.
